2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up

References

• Golomb H M, Catovsky D, Golde D W. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978; 89: 677–683
   PubMed Web of Science ®Google Scholar
• Piro L D, Carrera C J, Carson D A, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Spiers A S, Moore D, Cassileth P A, Harrington D P, Cummings F J, Neiman R S, et al. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987; 316: 825–830
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Kempin S, Gee T, Tran L L, Clarkson B. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990; 75: 839–845
   PubMed Web of Science ®Google Scholar
• Grever M, Kopecky K, Foucar M K, Head D, Bennett J M, Hutchison R E, et al. Randomized comparison of pentostatin vs interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974–982
   PubMed Web of Science ®Google Scholar
• Flandrin G, Sigaux F, Sebahoun G, Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 1984; 11(Suppl 2)458–471
   PubMed Web of Science ®Google Scholar
• Golomb H M, Vardiman J W. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983; 61: 349–352
   PubMed Web of Science ®Google Scholar
• Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47: 2066–2076
   PubMed Web of Science ®Google Scholar
• Jansen J, Hermans J, Remme J, den Ottolander G J, Cardozo P L. Hairy cell leukaemia. Clinical features and effect of splenectomy. Scand J Haematol 1978; 21: 60–71
   PubMedGoogle Scholar
• Damasio E E, Frassoldati A. Splenectomy following complete response to alpha interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of the HCL88 protocol. Italian Cooperative Group for the Study of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma 1994; 14(Suppl 1)95–98
   PubMed Web of Science ®Google Scholar
• Federico M, Frassoldati A, Lamparelli T, Foa R, Brugiatelli M, Annino L, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994; 5: 725–731
   PubMed Web of Science ®Google Scholar
• Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 1994; 13: 307–316
   PubMed Web of Science ®Google Scholar
• Tallman M S, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–2474
   PubMed Web of Science ®Google Scholar
• Seto S, Carrera C J, Kubota M, Wasson D B, Carson D A. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Estey E H, Kurzrock R, Kantarjian H M, O'Brien S M, McCredie K B, Beran M, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888–894
   PubMed Web of Science ®Google Scholar
• Tallman M S, Hakimian D, Variakojis D, Koslow D, Sisney G A, Rademaker A W, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203–2209
   PubMed Web of Science ®Google Scholar
• Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 125 years. Cancer 2005; 104: 2442–2448
   PubMed Web of Science ®Google Scholar
• Cheson B D, Sorensen J M, Vena D A, Montello M J, Barrett J A, Damasio E, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007–3015
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Tani M, Marchi E, Stefoni V, Alinari L, Musuraca G, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004; 89: 309–313
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker A W, Mendiratta P, Kim B, Evanchuk D M, Hakimian D, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106: 241–246
   PubMed Web of Science ®Google Scholar
• Ratain M J, Vardiman J W, Barker C M, Golomb H M. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer 1988; 62: 2420–2424
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol J A, Piro L D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–1926
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476–1481
   PubMed Web of Science ®Google Scholar
• Dearden C E, Matutes E, Hilditch B L, Swansbury G J, Catovsky D. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106: 515–519
   PubMed Web of Science ®Google Scholar
• Filleul B, Delannoy A, Ferrant A, Zenebergh A, Van Daele S, Bosly A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8: 1153–1156
   PubMed Web of Science ®Google Scholar
• Ellison D J, Sharpe R W, Robbins B A, Spinosa J C, Leopard J D, Saven A, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84: 4310–4315
   PubMed Web of Science ®Google Scholar
• Sausville J E, Salloum R G, Sorbara L, Kingma D W, Raffeld M, Kreitman R J, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003; 119: 213–217
   PubMed Web of Science ®Google Scholar
• Wheaton S, Tallman M S, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556–1560
   PubMed Web of Science ®Google Scholar
• Tallman M S, Hakimian D, Kopecky K J, Wheaton S, Wollins E, Foucar K, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665–1670
   PubMed Web of Science ®Google Scholar
• Matutes E, Meeus P, McLennan K, Catovsky D. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997; 98: 375–383
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 2006; 130: 374–377
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73: 412–417
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen J L, O'Brien M, Verstovsek S S, Koller C A, Faderl S, et al. Eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL). Blood 2006; 107: 4658–4662
   PubMed Web of Science ®Google Scholar
• Seymour J F, Kurzrock R, Freireich E J, Estey E H. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906–2911
   PubMed Web of Science ®Google Scholar
• Seymour J F, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997; 11: 42–47
   PubMed Web of Science ®Google Scholar
• Urba W J, Baseler M W, Kopp W C, Steis R G, Clark J W, Smith J W, II, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73: 38–46
   PubMed Web of Science ®Google Scholar
• Goodman G R, Burian C, Koziol J A, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891–896
   PubMed Web of Science ®Google Scholar
• Au W Y, Klasa R J, Gallagher R, Le N, Gascoyne R D, Connors J M. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood 1998; 92: 1160–1164
   PubMed Web of Science ®Google Scholar
• Cheson B D, Vena D A, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454–2460
   PubMed Web of Science ®Google Scholar
• Federico M, Zinzani P L, Frassoldati A, Vinceti M, Mode A, Annino L, et al. Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 2002; 20: 638–646
   PubMed Web of Science ®Google Scholar
• Flinn I W, Kopecky K J, Foucar M K, Head D, Bennett J M, Hutchison R, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981–2986
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Strom S S, Estey E, O'Brien S, Keating M J, Jiang H, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997; 15: 1803–1810
   PubMed Web of Science ®Google Scholar
• Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17: 45–51
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102: 810–813
   PubMed Web of Science ®Google Scholar
• Thomas D A, O'Brien S, Bueso-Ramos C, Faderl S, Keating M J, Giles F J, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906–3911
   PubMed Web of Science ®Google Scholar
• Kreitman R J, Wilson W H, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann T A, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340–3348
   PubMed Web of Science ®Google Scholar
• Kreitman R J, Wilson W H, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald D J, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241–247
   PubMed Web of Science ®Google Scholar
• Bang S, Nagata S, Onda M, Kreitman R J, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005; 11: 1545–1550
   PubMed Web of Science ®Google Scholar
• von Rohr A, Schmitz S F, Tichelli A, Hess U, Piguet D, Wernli M, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13: 1641–1649
   PubMed Web of Science ®Google Scholar
• Hoffman M A, Janson D, Rose E, Rai K R. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 1997; 15: 1138–1142
   PubMed Web of Science ®Google Scholar
• Kreitman R J, Squires D R, Stetler-Stevenson M, Noel P, FitzGerald D J, Wilson W H, et al. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719–6729
   PubMed Web of Science ®Google Scholar
• Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046–1050
   PubMed Web of Science ®Google Scholar
• Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115: 609–611
   PubMed Web of Science ®Google Scholar